A PHASE 1, OPEN- LABEL STUDY TO EVALUATE THE MULTIPLE DOSE PHARMACOKINETICS OF DANUGLIPRON FOLLOWING ORAL ADMINISTRATION IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY
Latest Information Update: 22 Jan 2025
At a glance
- Drugs Danuglipron (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Pfizer
- 20 Jan 2025 Status changed from recruiting to completed.
- 16 Oct 2024 Status changed from active, no longer recruiting to recruiting.
- 10 Oct 2024 Status changed from recruiting to active, no longer recruiting.